NPH Neuropharm

 

TIDMNPH 
 
RNS Number : 5427P 
Neuropharm Group PLC 
26 March 2009 
 

+------------------------------------------+------------------------------------+ 
| For immediate release                    |                      26 March 2009 | 
+------------------------------------------+------------------------------------+ 
 
 
 
 
Neuropharm Group Plc 
("Neuropharm" or "the Company") 
 
 
Share Price Movement 
 
 
Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on 
developmental disorders, notes the existence of market rumour and the recent 
movement in its share price.  The Company confirms that it received an 
indicative indication of interest with respect to a possible M&A transaction 
from a third party and that this interest is not being pursued.  It further 
confirms that it is not currently in M&A discussions and is not aware of any 
specific reason for the share price movement. 
 
 
As detailed in the Company's half-year report for the six months ended 31 
December 2008, announced on 17 March 2009, the Company had cash, cash 
equivalents and money market investments of GBP10.2 million at 31 December 2008. 
 As noted in the joint statement from the Chairman and Chief Executive Officer, 
the Company is undertaking a detailed analysis and review of the future 
strategic alternatives for its lead programme NPL-2008 and for the Company, 
including the possibility of partnering NPL-2008 with a much larger 
pharmaceutical company. 
 
 
 
 
For further information please contact: 
 
 
+-----------------------------------------------+--------------------+ 
| Neuropharm                                    |  + 44 (0) 1372 371 | 
|                                               |                171 | 
+-----------------------------------------------+--------------------+ 
| Robert Mansfield, Chief Executive Officer     |                    | 
| Graham Yeatman, Chief Financial Officer       |                    | 
+-----------------------------------------------+--------------------+ 
|                                               |                    | 
+-----------------------------------------------+--------------------+ 
| Piper Jaffray Ltd.                            |   + 44 (0) 20 3142 | 
|                                               |               8700 | 
+-----------------------------------------------+--------------------+ 
| Neil Mackison, Rupert Winckler                |                    | 
+-----------------------------------------------+--------------------+ 
|                                               |                    | 
+-----------------------------------------------+--------------------+ 
| Buchanan Communications                       |   + 44 (0) 20 7466 | 
|                                               |               5000 | 
+-----------------------------------------------+--------------------+ 
| Mark Court, Mary-Jane Johnson, Catherine      |                    | 
| Breen                                         |                    | 
+-----------------------------------------------+--------------------+ 
 
 
Notes to Editors: 
 
 
About Neuropharm 
Neuropharm is a speciality pharmaceutical company focused on the development of 
medicines for the treatment and management of neurodevelopmental disorders. 
Please visit www.neuropharm.co.uk for further information. 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 SPMJFMTTMMTTBTL 
 

Neuropharm (LSE:NPH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024

Neuropharm (LSE:NPH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024